PR84338

FLORENCE, Italy, June 11, 2020 /PRNewswire=KYODO JBN/ --

- Turnover reaches Euros 3,793 million, with an increase of 3.2% compared to

2018 and EBITDA of Euros 492 million thanks to continued strong performance of

its most important products

- Euros 150 million investment into new plant in Italy significantly increasing

oral blister capacity in line with increased demand

- Completion of Stemline acquisition, a US based biopharmaceutical company,

marks Menarini Group's pivotal entry into the world's largest pharma market

Menarini Group, a privately held Italian pharmaceutical and diagnostics

company, announced its 2019 results.

Turnover reaches nearly Euros 3.8 billion (Euros 3,793 million), with an

increase of 3.2% compared to2018, and EBITDA of Euros 492 million. Growth was

mainly driven by international markets despite the patent expiration of

Adenuric (febuxostat), a drug for hyperuricemia. The year that ended was

obviously not affected by the COVID-19 crisis and saw Menarini increase its

presence abroad with international turnover reaching 77% of the global total.

Elcin Barker Ergun, CEO of Menarini Group, commented, "2019 was another year of

solid operating performance for Menarini with continued top-line growth despite

a major patent loss. In line with continued strong growth of our most important

products, we have just announced a major new manufacturing site investment in

Florence to significantly increase our oral blisters capacity. Looking ahead,

we remain focused on our strategic priorities in primary and specialty care to

serve millions of patients around the world. The acquisition of Stemline, a New

York-based US biopharmaceutical company, which we have just completed is a key

move in line with our strategy providing us an excellent foundation to tap into

the world's largest pharmaceutical market and greatly enhancing our innovation power."

About Menarini

The Menarini Group is a leading international pharmaceutical company with a

presence in over 100 countries, including a direct presence in over 70

countries. Its global platform extends throughout Europe, Central America,

Africa, the Middle East and Asia and generates nearly over Euros 3.8 billion in

annual sales. For over 125 years, Menarini has been investing in the

development and commercial distribution of pharmaceuticals to serve patients

and physicians around the world with a full portfolio of products in the

cardiovascular, gastroenterology, metabolic, infectious diseases and

anti-inflammatory/analgesic therapeutic areas. Menarini is also committed to

oncology, with several new investigational drugs in development for the

treatment of a variety of tumors.

Photo - https://mma.prnewswire.com/media/1179000/Menarini_Group.jpg

Logo - https://mma.prnewswire.com/media/652491/MENARINI_Group_Logo.jpg

Source: Menarini I.F.R.